Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis.

Foiadelli T, Savasta S, Battistone A, Kota M, Passera C, Fiore S, Bino S, Amato C, Lozza A, Marseglia GL, Fiore L.

BMC Infect Dis. 2016 Jun 10;16:277. doi: 10.1186/s12879-016-1587-y.

2.

Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Amanna IJ, Slifka MK.

Expert Rev Vaccines. 2016 Dec;15(12):1519-1533. Epub 2016 Jun 20. Review.

3.

Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines.

Mahaux O, Bauchau V, Van Holle L.

Pharmacoepidemiol Drug Saf. 2016 Feb;25(2):215-22. doi: 10.1002/pds.3918. Epub 2015 Nov 25. Review. No abstract available.

4.

History of polio vaccination.

Baicus A.

World J Virol. 2012 Aug 12;1(4):108-14. doi: 10.5501/wjv.v1.i4.108.

5.

Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS; GeoSentinel Yellow Fever Working Group.

Emerg Infect Dis. 2001 Nov-Dec;7(6):945-51.

6.

Natural genetic exchanges between vaccine and wild poliovirus strains in humans.

Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F, Crainic R.

J Virol. 2000 Sep;74(18):8434-43.

7.

Polio vaccine: is it time for a change?

Finn A, Bell F.

Arch Dis Child. 1998 Jun;78(6):571-3; discussion 573-4. No abstract available.

8.

The complicated task of monitoring vaccine safety.

Ellenberg SS, Chen RT.

Public Health Rep. 1997 Jan-Feb;112(1):10-20; discussion 21. Review.

Supplemental Content

Support Center